0.36
—
Close of 9 Nov 2026, in HKD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Wai Yuen Tong Medicine Holdings
Its shares trade on HKEX under the ticker 897.HK. It has been listed since 31 October 1997. In the fiscal year to 31 March 2025, it reported revenue of HK$745.3m and net income of HK$7.1m. At that date it held total assets of HK$1.74bn and shareholders' equity of HK$1.18bn.
Wai Yuen Tong Medicine Holdings Ltd. is an investment holding company, which engages in the production and sale of pharmaceutical products. The company employs 1,941 full-time employees The firm operates through three segments. Production and Sale of Chinese Pharmaceutical and Health Food Products segment is mainly engaged in the manufacture, processing and retailing of traditional Chinese medicine in China and Hong Kong. Its products include Chinese medicines under the brand Wai Yuen Tong, as well as products manufactured with traditional prescriptions. Production and Sale of Western Pharmaceutical and Health Food Products segment is engaged in the processing and sales of Western pharmaceutical products and personal care products under the brands Madame Pearl’s and Pearl’s. Property Investment segment is engaged in the investment in commercial properties for rental income.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 31 Oct 1997
- Employees
- 1,941
- Website
- wyth.net ↗
Leadership
Pay as last reported
- Mr. Ching Ho TangExecutive Chairman of the Board, Managing Director, since 2001HK$8.7m
- Mr. Seung Ming WongFinancial Controller
- Ms. Man Yee LawExecutive Director, since 2021HK$788,000
- Ms. Wai Man TangExecutive Director, since 2018HK$1.3m
- Mr. Siu Fai ChanHead of Factory Operations
- Mr. Kam Wing MakGeneral Manager - Luxembourg Medicine Group
- Dr. Yuen Wo TsangDirector - Technical
- Ms. Yee Man NgCompany Secretary
- Prof. Wing Kwong ChanIndependent Non-Executive Director
- Mr. Ka Fai LiIndependent Non-Executive DirectorHK$204,000
- Prof. Wing Hang SitIndependent Non-Executive Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Wai Yuen Tong brand produces traditional Chinese medicine in China and Hong Kong with 1,941 employees.
- Madame Pearl’s and Pearl’s brands offer Western pharmaceutical and personal care products effectively.
- Property Investment segment generates rental income from commercial properties in Hong Kong.
Weaknesses
- Production and Sale of Chinese Pharmaceutical segment relies on traditional prescriptions in China.
- Western Pharmaceutical segment uses Madame Pearl’s and Pearl’s brands for limited market reach.
- Property Investment segment depends on commercial properties for rental income only.
Opportunities
- Expanding Chinese Pharmaceutical segment into new markets within China and Hong Kong.
- Increasing Western Pharmaceutical segment sales through Madame Pearl’s and Pearl’s brands.
- Growing Property Investment segment by acquiring more commercial properties in Hong Kong.
Threats
- Competition from other pharmaceutical companies in the Health Care sector.
- Regulatory changes affecting traditional Chinese medicine production in China.
- Economic downturn impacting commercial property rental income in Hong Kong.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.